Pro Investor research
Sign in to continue.
Full company research for this company is part of the Pro Investor membership: Pro Investor Scores and rankings, the full screener, valuation and capital returns intelligence, ownership and insider evidence, signals and alerts. Company identity, coverage depth and the education library stay free.
AHCO · NASDAQ
ADAPTHEALTH CORP
Private betaSector unavailable · Industry unavailable
$6.06
+3.59%
Close on Sep 11, 2026
Updated 12/19/2023
Long-term research evidence only. No price targets, no trading signals, no recommendations.
Appears in
Membership means the company satisfied a published rule on the latest research build. It is not a recommendation.
Learn the metrics on this page
Plain-English definitions, with the formula and the limitations of each measure.
In the company’s own words
What this company does
AdaptHealth Corp. and subsidiaries ("AdaptHealth" or "the Company") is a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment ("HME"), medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. A description of the products and services provided within each of the Company’s four reportable segments is provided below.
The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea.
The Respiratory Health segment provides oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services to individuals for the treatment of respiratory diseases, such as chronic obstructive pulmonary disease and chronic respiratory failure.
The Diabetes Health segment provides medical devices, including continuous glucose monitors and insulin pumps, and related services to patients for the treatment of diabetes.
Quoted from the business section of this company’s 10-K filed February 24, 2026. Read the filing
General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.